Literature DB >> 9831319

Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation.

N J Goulding1, H S Euzger, S K Butt, M Perretti.   

Abstract

Neutrophils have been implicated in mediating much of the tissue damage associated with chronic inflammatory diseases such as rheumatoid arthritis, where they are involved in destruction of both cartilage and bone. Glucocorticoids are powerful anti-inflammatory agents, often used in the treatment of this autoimmune disease. They exert significant inhibitory effects on neutrophil activation and functions, such as chemotaxis, adhesion, transmigration, apoptosis, oxidative burst, and phagocytosis. The mechanisms by which glucocorticoids exert these effects on neutrophils are unclear. Evidence from studies of inflammation in human subjects and animal models suggests that annexin-I an endogenous, glucocorticoid-induced protein also known as lipocortin-1, has a pivotal role in modulating neutrophil activation, transmigratory, and phagocytic functions. Furthermore, we present evidence for altered neutrophil functions in rheumatoid arthritis that correspond to a significantly reduced capacity of these cells to bind annexin-I. A proposed novel pathway for glucocorticoid actions on neutrophils involving annexin-I could explain the development of chronic neutrophil activation in diseases such as rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9831319     DOI: 10.1007/s000110050310

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  26 in total

Review 1.  Present concepts on the inflammatory modulators with special reference to cytokines.

Authors:  A S J P A M Van Miert
Journal:  Vet Res Commun       Date:  2002-02       Impact factor: 2.459

2.  Impaired phagocytic mechanism in annexin 1 null macrophages.

Authors:  Simon Yona; Sigrid E M Heinsbroek; Leanne Peiser; Siamon Gordon; Mauro Perretti; Roderick J Flower
Journal:  Br J Pharmacol       Date:  2006-04-24       Impact factor: 8.739

3.  Stimulus-specific defect in the phagocytic pathways of annexin 1 null macrophages.

Authors:  Simon Yona; Julia C Buckingham; Mauro Perretti; Roderick J Flower
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

4.  Expression and function of MIP-2 are reduced by dexamethasone treatment in vivo.

Authors:  R Schramm; Q Liu; H Thorlacius
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 5.  Glucocorticoids and central nervous system inflammation.

Authors:  Klaus Dinkel; William O Ogle; Robert M Sapolsky
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

6.  Dexamethasone induces the secretion of annexin I in immature lymphoblastic cells by a calcium-dependent mechanism.

Authors:  M Castro-Caldas; C B Duarte; A P Carvalho; M C Fernandes Lopes
Journal:  Mol Cell Biochem       Date:  2002-08       Impact factor: 3.396

7.  Steroids prevent late extension of radiofrequency lesions in the thigh muscle of infant rats: implications for pediatric ablation.

Authors:  Guilherme Fenelon; Rinaldo Fernandes; Marcello Franco; Angelo A V de Paola
Journal:  J Interv Card Electrophysiol       Date:  2003-08       Impact factor: 1.900

8.  Prostaglandins mediate zymosan-induced sickness behavior in mice.

Authors:  Juliana B M Lima; Clarice C Veloso; Fabiana C Vilela; Alexandre Giusti-Paiva
Journal:  J Physiol Sci       Date:  2016-10-03       Impact factor: 2.781

9.  Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis.

Authors:  Eric Hyun; Manlio Bolla; Martin Steinhoff; John L Wallace; Piero Del Soldato; Nathalie Vergnolle
Journal:  Br J Pharmacol       Date:  2004-08-16       Impact factor: 8.739

10.  Immunomodulatory effects of domoic acid differ between in vivo and in vitro exposure in mice.

Authors:  Milton Levin; Heather Leibrecht; James Ryan; Frances Van Dolah; Sylvain De Guise
Journal:  Mar Drugs       Date:  2008-12-22       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.